Baxter International Inc. issued the following announcement on Feb. 12.
- Compact, portable monitor that accurately measures patient’s resting energy expenditure to help optimize nutrition therapy
- Technology replaces potentially inaccurate predictive equations
- Expected to launch in the United States at ASPEN Conference in March 2020
As part of its partnership with COSMED, Baxter has rights to bring Q-NRG+ to at least 18 markets around the globe, with the potential for further expansion. The 510(k) clearance is the latest regulatory approval for Q-NRG+, which is currently available in 12 countries in Europe as well as Canada, Australia and New Zealand.
Hospital malnutrition is a serious public health issue in the United States. Approximately two million hospital stays in the U.S. involve malnutrition,2 and almost a quarter of U.S. patients with malnutrition were readmitted to the hospital within 30 days of discharge.3 Hospitalized patients with malnutrition may require PN therapy if they cannot be fed orally or enterally (tube feeding).
Traditional methods of estimating caloric requirements use predictive equations that are based on factors like weight, height, gender and age. However, research has shown that these equations often result in inaccurate measurements and could result in overfeeding or underfeeding.4,5
“It can be challenging to prescribe clinical nutrition without knowing the exact caloric needs of a patient,” said Heather Knight, general manager, U.S. Hospital Products, Baxter. “With Q-NRG+, clinicians will have access to the latest technology to accurately measure energy requirements and won’t have to rely on predictive equations or dated technology — which can be cumbersome and time consuming.”
Q-NRG+ is designed around flexibility and hospital efficiency, and features a compact, portable design that can be easily moved between patient rooms. The device requires minimal time to warm-up and calibrates automatically between uses. Q-NRG+ can be used to test both adult and pediatric patients, as well as spontaneously breathing or mechanically ventilated patients.
Indications for Use
The Q-NRG+ portable metabolic monitors are indicated for the measurement of resting energy expenditure (REE) for spontaneously breathing and ventilated patients, within the following populations:
- Spontaneously breathing subjects weighing more than 15 kilograms (33 pounds) when using a canopy.
- Spontaneously breathing subjects more than 6 years old and weighing more than 10 kilograms (22 pounds) when using a face mask.
- Ventilated subjects more than 10 years old and weighing more than 10 kilograms (22 pounds).
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
About COSMED
COSMED, established in 1980, is a privately-owned company that designs and manufactures cardio pulmonary and metabolic diagnostic equipment. COSMED solutions address needs of the healthcare, academic and industry markets to assess human metabolism, exercise physiology, pulmonary function and body composition for clinical and research purposes. COSMED products include a full range of spirometers, indirect calorimetry, cardio pulmonary exercise testing and body composition systems including software. COSMED headquarters are located in Rome, Italy with direct operations in Australia, France, Germany, Hong Kong, Netherlands, Switzerland, UK and United States, and a network of business partners covering more than 80 countries. Visit www.cosmed.com to know more about COSMED.
Original source can be found here.
